Package Leaflet: Information for the User
Ezetimibe/Atorvastatin Zentiva 10 mg/10 mg film-coated tablets EFG
Ezetimibe/Atorvastatin Zentiva 10 mg/20 mg film-coated tablets EFG
Ezetimibe/Atorvastatin Zentiva 10 mg/40 mg film-coated tablets EFG
Ezetimibe/Atorvastatin Zentiva 10 mg/80 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Ezetimibe/Atorvastatin Zentiva is a medicine that lowers high cholesterol levels. This medicine contains ezetimibe and atorvastatin.
Ezetimibe/atorvastatin is used in adults to lower the levels of total cholesterol, "bad" cholesterol (LDL cholesterol) and certain fats (triglycerides) in the blood. It also raises the levels of "good" cholesterol (HDL cholesterol).
Ezetimibe/atorvastatin works by reducing cholesterol in two ways. It reduces the amount of cholesterol absorbed in the gut and also the amount of cholesterol made by the body.
Cholesterol is one of the fats (lipids) found in the bloodstream. Your total cholesterol is made up mainly of LDL and HDL cholesterol.
LDL cholesterol is often called "bad" cholesterol because it can build up in the walls of your arteries, forming plaques. Over time, this can lead to a narrowing of the arteries, which can reduce or block blood flow to vital organs such as the heart and brain. This blocking of blood flow can lead to a heart attack or stroke.
HDL cholesterol is often called "good" cholesterol because it helps prevent "bad" cholesterol from building up in the arteries and protects against heart disease.
Triglycerides are another type of fat found in the blood that can increase the risk of heart disease.
Ezetimibe/atorvastatin is used in patients who cannot control their cholesterol levels by diet alone. While taking this medicine, you should also follow a low-cholesterol diet.
Ezetimibe/atorvastatin is used, along with a low-cholesterol diet, if you have:
Ezetimibe/atorvastatin does not help you lose weight.
Do not takeEzetimibe/Atorvastatin Zentiva
Warnings and precautions
Tell your doctor or pharmacist before you start taking this medicine if:
Tell your doctor as soon as possible if you experience unexplained muscle pain, tenderness or weakness while taking ezetimibe/atorvastatin.This is because, on rare occasions, muscle problems can be serious, including muscle breakdown resulting in kidney damage. Atorvastatin can cause muscle problems and muscle problems have also been reported with ezetimibe.
Also tell your doctor or pharmacist if you experience persistent muscle weakness. Further tests and medicines may be needed to diagnose and treat this condition.
Tell your doctor or pharmacist before you start taking this medicine:
If you are in any of the above situations (or are unsure), consult your doctor before taking this medicine, as your doctor will need to perform a blood test before starting your treatment with ezetimibe/atorvastatin, and possibly during treatment, to predict the risk you have of experiencing muscle side effects. The risk of muscle side effects, e.g. rhabdomyolysis, increases when certain medicines are taken at the same time (see section 2 "Other medicines and Ezetimibe/Atorvastatin Zentiva").
While you are taking this medicine, your doctor will check if you have diabetes or are at risk of developing diabetes. This risk of diabetes increases if you have high levels of sugars and fats in the blood, are overweight and have high blood pressure.
Tell your doctor about all your medical conditions, including allergies.
The combined use of ezetimibe/atorvastatin and fibrates (certain medicines used to lower cholesterol) should be avoided, as the combined use of ezetimibe/atorvastatin and fibrates has not been studied.
Children
Ezetimibe/atorvastatin is not recommended for use in children and adolescents.
Other medicines and Ezetimibe/Atorvastatin Zentiva
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
There are some medicines that may affect the way ezetimibe/atorvastatin works or their effects may be altered by ezetimibe/atorvastatin (see section 3). This type of interaction could reduce the effect of one or both medicines. Alternatively, it could increase the risk or severity of side effects, including the serious muscle damage known as rhabdomyolysis described in section 4:
** If you have to take fusidic acid by mouth to treat a bacterial infection, you will need to stop taking this medicine temporarily. Your doctor will tell you when you can restart taking ezetimibe/atorvastatin. The use of ezetimibe/atorvastatin with fusidic acid can rarely cause muscle weakness, tenderness or pain (rhabdomyolysis). For more information about rhabdomyolysis, see section 4.
TakingEzetimibe/Atorvastatin Zentivawith food and drink
See section 3 for instructions on how to take Ezetimibe/Atorvastatin Zentiva. Please note the following:
Grapefruit juice
Do not take more than one or two small glasses of grapefruit juice per day because large quantities of grapefruit juice can affect the action of ezetimibe/atorvastatin.
Alcohol
Avoid excessive alcohol consumption while taking this medicine. For more details, see section 2 "Warnings and precautions".
Pregnancy and breast-feeding
Do not take ezetimibe/atorvastatin if you are pregnant, think you may be pregnant or are planning to become pregnant. Do not take ezetimibe/atorvastatin if you are able to become pregnant and are not using reliable contraception.
If you become pregnant while taking ezetimibe/atorvastatin, stop taking it immediately and tell your doctor.
Do not take ezetimibe/atorvastatin if you are breast-feeding.
The safety of ezetimibe/atorvastatin during pregnancy and breast-feeding has not yet been established.
Ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
Ezetimibe/atorvastatin is unlikely to affect your ability to drive or use machines. However, it should be taken into account that some people experience dizziness after taking ezetimibe/atorvastatin.
Ezetimibe/Atorvastatin Zentivacontains lactose and sodium
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Always take this medicine exactly as your doctor has told you. Your doctor will determine the appropriate dose of ezetimibe/atorvastatin for you, depending on your current treatment and your personal risk factors.
If you are unsure, consult your doctor again.
How much to take
The recommended dose is one ezetimibe/atorvastatin tablet once a day by mouth.
Method of administration
Take ezetimibe/atorvastatin at any time of day. You can take it with or without food.
If your doctor has prescribed ezetimibe/atorvastatin with colestyramine or any other bile acid sequestrant (medicines that lower cholesterol), you should take ezetimibe/atorvastatin at least 2 hours before or 4 hours after taking the bile acid sequestrant.
If you take moreEzetimibe/Atorvastatin Zentivathan you should
Consult your doctor or pharmacist.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount taken.
If you forget to takeEzetimibe/Atorvastatin Zentiva
Do not take a double dose to make up for forgotten doses. Simply take your normal dose of this medicine at the usual time the next day.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
If you experience any of the following serious adverse effects or symptoms, stop taking your tablets and inform your doctor immediately, or go to the emergency department of the nearest hospital.
Consult your doctor as soon as possible if you experience problems associated with the unexpected or unusual appearance of bleeding or bruising, as this fact may be indicative of liver disease.
Other Possible Adverse Effects with Ezetimibe/Atorvastatin Zentiva
Frequent: may affect up to 1 in 10 people
Infrequent: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Frequency not known: the frequency cannot be estimated from the available data
Additionally, the following adverse effects have been reported in people taking ezetimibe/atorvastatin, ezetimibe, or atorvastatin tablets:
Consult your doctor if you experience weakness in the arms or legs that worsens after periods of activity, double vision, or drooping eyelids, difficulty swallowing, or breathing difficulties.
Possible Adverse Effects Reported with Some Statins
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is an adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the box after CAD. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be thrown down the drain or into the trash. Deposit the packaging and medicines you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Ezetimibe/Atorvastatin Zentiva
The active ingredients are ezetimibe and atorvastatin. Each film-coated tablet contains 10 mg of ezetimibe and 10 mg, 20 mg, 40 mg, or 80 mg of atorvastatin (as atorvastatin calcium trihydrate).
The other ingredients are calcium carbonate; anhydrous colloidal silica; sodium croscarmellose; hypromellose, lactose monohydrate, povidone, magnesium stearate, microcrystalline cellulose, polysorbate 80, sodium lauryl sulfate (E487).
The tablet coating contains: hypromellose, lactose monohydrate, titanium dioxide (E171), macrogol, talc.
Appearance of the Product and Package Contents
White to off-white, film-coated, biconvex, capsule-shaped tablets.
Ezetimibe/Atorvastatin Zentiva 10 mg/10 mg film-coated tablets EFG: with "1T" engraved on one side
Ezetimibe/Atorvastatin Zentiva 10 mg/20 mg film-coated tablets EFG: with "2T" engraved on one side
Ezetimibe/Atorvastatin Zentiva 10 mg/40 mg film-coated tablets EFG: with "4T" engraved on one side
Ezetimibe/Atorvastatin Zentiva 10 mg/80 mg film-coated tablets EFG: with "8T" engraved on one side
Package size:
10, 30, 90, and 100 film-coated tablets in aluminum/aluminum blisters.
Not all package sizes may be marketed.
Marketing Authorization Holder
Zentiva, k.s.
U Kabelovny 130
Dolní Mecholupy
102 37 Prague 10
Czech Republic
Manufacturer
Delorbis Pharmaceuticals Limited
Industrial Area
Athinon 17
2643 Ergates
Nicosia
Cyprus
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Zentiva Spain S.L.U.
Avenida de Europa, 19, Edificio 3, Planta 1.
28224 Pozuelo de Alarcón, Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany | Atorvastatin Ezetimib Zentiva 10 mg/ 10 mg film-coated tablets Atorvastatin Ezetimib Zentiva 20 mg/ 10 mg film-coated tablets Atorvastatin Ezetimib Zentiva 40 mg/ 10 mg film-coated tablets Atorvastatin Ezetimib Zentiva 80 mg/ 10 mg film-coated tablets |
Bulgaria | ??????? 10 mg /10 mg ????????? ???????? ??????? 20 mg /10 mg ????????? ???????? ??????? 40 mg /10 mg ????????? ???????? ??????? 80 mg /10 mg ????????? ???????? |
Spain | Ezetimiba/Atorvastatina Zentiva 10 mg/10 mg film-coated tablets EFG Ezetimiba/Atorvastatina Zentiva 10 mg/20 mg film-coated tablets EFG Ezetimiba/Atorvastatina Zentiva 10 mg/40 mg film-coated tablets EFG Ezetimiba/Atorvastatina Zentiva 10 mg/80 mg film-coated tablets EFG |
France | EZETIMIBE/ATORVASTATINE ZENTIVA 10 mg/10 mg, film-coated tablet EZETIMIBE/ATORVASTATINE ZENTIVA 10 mg/20 mg, film-coated tablet EZETIMIBE/ATORVASTATINE ZENTIVA 10 mg/40 mg, film-coated tablet EZETIMIBE/ATORVASTATINE ZENTIVA 10 mg/80 mg, film-coated tablet |
Italy | Zetovar |
Ireland | Ezetimibe/ Atorvastatin Zentiva 10 mg/10 mg film-coated tablets Ezetimibe/ Atorvastatin Zentiva 10 mg/20 mg film-coated tablets Ezetimibe/ Atorvastatin Zentiva 10 mg/40 mg film-coated tablets Ezetimibe/ Atorvastatin Zentiva 10 mg/80 mg film-coated tablets |
Netherlands | Zetovar 10 mg/10 mg film-coated tablets Zetovar 10 mg/20 mg film-coated tablets Zetovar 10 mg/40 mg film-coated tablets Zetovar 10 mg/80 mg film-coated tablets |
Portugal | Atorvastatina + Ezetimiba Zentiva |
Date of the Last Revision of this Prospectus: February 2025
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/